BridgeBio Pharma, Inc. (BBIO) vs Exelixis, Inc. (EXEL)
- BridgeBio Pharma, Inc. BBIO 66.39 −1.10%
- Exelixis, Inc. EXEL 62.11 −1.15%
BridgeBio Pharma, Inc. and Exelixis, Inc. are both Biotechnology companies. Exelixis, Inc. is the larger, with a market value of $15.6B against $13.1B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 18.8×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs −97.0%) and the higher return on invested capital (60.5% vs 0.00%). Across the 18 metrics below, Exelixis, Inc. leads on 14 and BridgeBio Pharma, Inc. on 4.
Valuation
Profitability
| Metric | BBIO | EXEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.44% | 96.48% | 65.16% |
| Operating margin | (69.81%) | 39.88% | 0.00% |
| Net margin | (97.03%) | 35.33% | 0.00% |
| Free cash flow margin | (61.06%) | 47.55% | 0.00% |
| Return on equity | 32.31% | 44.39% | (56.36%) |
| Return on assets | (60.23%) | 33.28% | (48.04%) |
| Return on invested capital | 0.00% | 60.45% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack